We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

1 hedge funds and large institutions have $13K invested in Alexion Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less capital invested

Capital invested by funds: $14K → $13K (-$1K)

50% less funds holding

Funds holding: 2 → 1 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RG
1
Retirement Group
California
$13K – – –

ALXN Hedge Fund Activity: Q1 2022 in Review

1 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2022, worth a combined $13K — down 7.1% from $14K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of ALXN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

  • 1 institutional investor held Alexion Pharmaceuticals (ALXN) as of Q1 2022, down from 2 in Q4 2021.
  • Funds reported $13K of Alexion Pharmaceuticals stock for Q1 2022, down 7.1% quarter-over-quarter.
  • 0 funds opened new Alexion Pharmaceuticals positions in Q1 2022 and 1 closed out, a net change of -1 holder.

Based on aggregated 13F filings for Q1 2022.